Another randomized multicenter study was conducted by Seynaeve and collegues [4] and included 535 chemotherapy- naive patients receiving cisplatin, 50-120 mg/m 2. Patients were randomized to receive ...

June 29, 2012 — A single 32-mg intravenous dose of ondansetron (Zofran, GlaxoSmithKline [ondansetron hydrochloride], and generics) may affect QT interval prolongation, the US Food and Drug ...

PHILADELPHIA--(BUSINESS WIRE)-- Lannett Company, Inc. (AMEX: LCI), a manufacturer of generic pharmaceuticals, announced today that it has received approval from the U.S. Food and Drug Administration ...

Ondansetron (Ond -R) is a 5-HT3 receptor antagonist, prescribed for nausea and vomiting caused by cancer chemotherapy, radiation therapy and surgery. It blocks serotonin receptors in the vomiting ...

Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. In a double-blind, randomized, stratified, parallel-group study, the efficacy and safety of granisetron and ...

Nausea and vomiting (emesis) remain among the most feared side effects of treatment for patients with cancer about to begin chemotherapy. Uncontrolled emesis can adversely affect patient quality of ...

Ondansetron oral tablet is a generic drug that’s prescribed for nausea and vomiting in certain situations. Ondansetron has interactions with some other drugs and supplements, including certain ...

FDA pulls high-dose Zofran The anti-nausea drug ondansetron has been pulled from the market due to potential for serious cardiac risks. The 32 mg, single intravenous (IV) dose of the anti-nausea drug ...

Please provide your email address to receive an email when new articles are posted on . The 32-mg, single IV dose of ondansetron hydrochloride no longer will be marketed because of the potential for ...

Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please ...